Soligenix Inc. SNGX Archives

TuesdayApr 08, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation

Recent Zacks report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix. The Zacks report underscores Soligenix's strategic focus on rare diseases and areas lacking effective treatments. Financially, Soligenix has demonstrated resilience amid the challenges inherent in biopharmaceutical development. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix's diverse product pipeline, financial health and strategic positioning within the biopharmaceutical industry.…

ThursdayApr 03, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate,…

TuesdayMar 25, 2025 9:20 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from roughly $60 million in non-dilutive funding and a pipeline that includes multiple orphan and fast-track designations, the company is preparing for potential regulatory approvals. IBN will amplify Soligenix’s message through its expansive media and investor network. To view the full article, visit https://ibn.fm/7hzf1 About Soligenix…

FridayMar 21, 2025 11:50 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year ended Dec. 31, 2024. “We remain highly focused on advancing our multiple clinical programs as we work towards achieving a number of important and potentially transformational development milestones, including top-line results in 2026 for our actively enrolling confirmatory Phase 3 placebo-controlled study evaluating HyBryte(TM) (synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (‘CTCL’),” stated Christopher J. Schaber, PhD, president and chief executive officer…

TuesdayMar 18, 2025 12:41 pm

QualityStocksNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads a recent article. “With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.” To view the full article, visit https://ibn.fm/B722I About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing…

ThursdayMar 13, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix has multiple late-stage assets with orphan and fast-track designations, providing a clear regulatory pathway toward potential approvals. The company’s pipeline has a total addressable market exceeding $2 billion, spanning rare diseases, inflammation, and biothreat applications. Soligenix has benefited from significant non-dilutive government funding, which reduces operational expenses and financial risk while supporting its public health initiatives. The company is well-positioned for multiple development and regulatory catalysts, and commercial milestones, with lead candidates in cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. Soligenix is led by an experienced management team with a strong track record of success. Soligenix (NASDAQ:…

Site Search

Company Search

Tag: Soligenix Inc. SNGX

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation

Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results

QualityStocksNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Market Basics

Newsletter Publishers

Public Companies